Literature DB >> 16887968

Endogenous myelin basic protein is presented in the periphery by both dendritic cells and resting B cells with different functional consequences.

Audrey Seamons1, Antoine Perchellet, Joan Goverman.   

Abstract

Multiple sclerosis is an inflammatory disease believed to be triggered by erroneous activation of self-reactive T cells specific for myelin proteins such as myelin basic protein (MBP). Inflammation is limited to the CNS, suggesting that the myelin-specific T cells encounter their Ags only after they cross the blood-brain barrier. However, our previous studies in mice showed that MBP epitopes are constitutively presented in lymphoid tissues. Here we identified which APCs in lymph nodes present endogenous MBP epitopes and determined the functional consequences of this presentation for both naive and activated MBP-specific T cells. Both CD8alpha+ and CD8alpha- dendritic cells were potent stimulators of proliferation for both naive and previously activated/memory MBP-specific T cells. Surprisingly, resting B cells also presented endogenous MBP that was acquired using a BCR-independent mechanism. Interaction with resting B cells triggered proliferation of both naive and activated MBP-specific T cells. Activated/memory MBP-specific T cells proliferating in response to resting B cells presenting endogenous MBP did not produce cytokines and became more refractory to subsequent stimulation. Interestingly, cytokine production by activated/memory T cells was triggered by resting B cells if the number of MBP epitopes presented was increased by adding exogenous MBP peptide. These results suggest that activated MBP-specific T cells may become less pathogenic in vivo following encounter with resting B cells presenting steady-state levels of endogenous MBP but can expand and remain pathogenic if the amount of MBP presented by B cells is increased, which could occur during chronic demyelinating disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887968     DOI: 10.4049/jimmunol.177.4.2097

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  Lineage targeted MHC-II transgenic mice demonstrate the role of dendritic cells in bacterial-driven colitis.

Authors:  Lillian Maggio-Price; Audrey Seamons; Helle Bielefeldt-Ohmann; Weiping Zeng; Thea Brabb; Carol Ware; Mingzu Lei; Robert M Hershberg
Journal:  Inflamm Bowel Dis       Date:  2013-01       Impact factor: 5.325

Review 3.  Immune tolerance in multiple sclerosis.

Authors:  Joan M Goverman
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

4.  Spinal activity of interleukin 6 mediates myelin basic protein-induced allodynia.

Authors:  Justin S Ko; Kelly A Eddinger; Mila Angert; Andrei V Chernov; Jennifer Dolkas; Alex Y Strongin; Tony L Yaksh; Veronica I Shubayev
Journal:  Brain Behav Immun       Date:  2016-03-09       Impact factor: 7.217

5.  B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system.

Authors:  Emily R Pierson; Ingunn M Stromnes; Joan M Goverman
Journal:  J Immunol       Date:  2013-12-23       Impact factor: 5.422

Review 6.  MHC class II antigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes.

Authors:  Xinjian Chen; Peter E Jensen
Journal:  Exp Mol Pathol       Date:  2008-04-13       Impact factor: 3.362

7.  Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis.

Authors:  Claus H Nielsen; Lars Börnsen; Finn Sellebjerg; Marie K Brimnes
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.